Report cover image

The Bispecific Antibody Revolution: Competitive Landscape Analysis and Market Disruption Assessment; Deep-Dive Intelligence on BNT327, Ivonescimab, and Emerging Dual-Target Platforms Challenging PD-1 Monotherapy Dominance

Publisher Bergner Medical Consulting
Published Nov 02, 2025
Length 29 Pages
SKU # BERM20574934

Description

The global immuno-oncology (IO) market is at a critical inflection point, with the era of single-agent PD-1/PD-L1 inhibitors giving way to multi-functional biologics. This market for bispecific antibodies (BsAbs) is projected to experience explosive growth, conservatively reaching between $15.1 billion and $22.4 billion by 2030 with more aggressive forecasts exceeding $110 billion in the long term. This report provides a comprehensive strategic analysis of this dynamic landscape, offering deep-dive intelligence on late-stage assets like BNT327 (Pumitamig) and Ivonescimab, which are challenging PD-1 monotherapy dominance in indications like NSCLC and ES-SCLC. It meticulously maps the competitive landscape, analyzing the clinical and commercial potential of next-generation dual-target platforms. This is an essential tool for R&D, business development, and strategic planning professionals seeking to understand the shift from monoclonal to bispecific antibody backbones in cancer treatment. Methodology:

This report combines extensive secondary research (SEC filings, conference abstracts, press releases) with secondary research insights from KOLs and analysis of regulatory breakthrough designations.

Key Highlights:

1. Detailed analysis of the next foundational backbone of cancer treatment.
2. Strategic profiles and financial data for key market players (Roche, BMS, Summit Therapeutics, BioNTech).
3. In-depth breakdown of BNT327/Ivonescimab's Phase 3 registrational trials (e.g., HARMONi-6, ROSETTA LUNG-01) and their potential to redefine standard of care.
4. Segmentation of the market by mechanism, target, and tumor type.

Table of Contents

29 Pages
I. Executive Summary
II. Market Disruption Assessment
2.1. The Shift from Monoclonals to Bispecifics
2.2. Global Market Size & Growth Forecast (2025-2035) and Key Drivers
III. Deep-Dive Competitive Profiles
3.1. BNT327 (Clinical & Commercial Strategy, Partnership Analysis)
3.2. Ivonescimab (Breakthrough Designation Analysis, HARMONi-6 Data)
3.3. Emerging Dual-Target Platforms
IV. Commercial and Clinical Landscape
4.1. Key Players and Portfolio Analysis (Roche, BMS, Summit, BioNTech)
4.2. Clinical Trial Mapping (Phase I-III, Target-Specific: PD-1/VEGF, CD3/BCMA)
V. Strategic Conclusions & Forecasts

Search Inside Report

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Request A Sample
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us